Results 71 to 80 of about 12,282,064 (142)

Refractory rhino-orbito-cerebral mucormycosis treated with intraconal amphotericin B. [PDF]

Arq Bras Oftalmol, 2022
Guimarães JA, Moura FC.
europepmc   +1 more source

[Management of cutaneous and systemic involvement by Candida auris]. [PDF]

Rev Esp Quimioter, 2022
Roig Martí C, Jiménez Sierra JJ, Pérez Catalán I, Gomila Sard S, Cardenal Álvarez A, Bellés Medall MD.   +5 more
europepmc   +1 more source

Primary cutaneous histoplasmosis difficult to treat in immunocompetent patient: case report and literature review. [PDF]

Einstein (Sao Paulo), 2021
Batista JM, Martins MAP, Bertollo CM.
europepmc   +1 more source

La anfotericina B en el tratamiento de la Leishmaniosis

, 2015
La leishmaniasis se define como un conjunto de enfermedades de presentación clínica muy variada, que se caracterizan por ser producidas por parásitos intracelulares obligados pertenecientes al género Leishmania. Esta patología se transmite principalmente
Romero Álvarez, Elia
core   +1 more source

Hyperbaric oxygen therapy as an adjunctive treatment for COVID-19-associated mucormycosis: a report of two cases. [PDF]

Rev Peru Med Exp Salud Publica, 2023
Valencia-Caballero V, Cachay-Diaz J, Huamán-Muñante J, Romaní-Montoro L, Vásquez-Zevallos N, Carozzi-Calvo C, Chian-García C, Hernández-Chávez H, Agustín-Paredes C, Rosa EV.   +9 more
europepmc   +1 more source

Perfil de pacientes portadores de leishmaniose visceral em uso de anfotericina b lipossomal em um hospital de referência de Teresina-PI

, 2018
The objective of this study was to analyze the profile of patients with Visceral Leshmaniasis treated with liposomal amphotericin B at a referral hospital in Teresina-PI. A total of 61 applications of liposomal amphotericin B treatment were performed for
da Silva Soares, Maria Clara, Martins Rocha, Nicolle Luz, do Nascimento, Paulo Pedro, Lira, Tainara Melo   +3 more
core  

Evidence map of diagnosis, treatment, prognosis, prevention, and control in visceral leishmaniasis. [PDF]

Rev Panam Salud Publica, 2022
Ibiapina AB, Batista FMA, Aguiar BGA, Mendonça VJ, Costa DL, Costa CHN, Abdala CVM.   +6 more
europepmc   +1 more source

Avaliação da resposta terapêutica ao emprego da anfotericina B no tratamento das modalidades cutânea e mucosa de leishmaniose em pacientes atendidos num Centro de referência no Rio de Janeiro entre 1989 e 2012

, 2014
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.A anfotericina B é medicamento de escolha no tratamento da leishmaniose tegumentar americana (LTA) para gestantes, quando não se obtém resposta com o ...
Nascimento, Maria Letícia Fernandes Oliveira
core   +1 more source

Formulation of Amphotericin B in PEGylated Liposomes for Improved Treatment of Cutaneous Leishmaniasis by Parenteral and Oral Routes. [PDF]

Pharmaceutics, 2022
Ramos GS, Vallejos VMR, Borges GSM, Almeida RM, Alves IM, Aguiar MMG, Fernandes C, Guimarães PPG, Fujiwara RT, Loiseau PM, Ferreira LAM, Frézard F.   +11 more
europepmc   +1 more source

Unexpected cause of ischemic lesions in an immunocompetent patient. [PDF]

Enferm Infecc Microbiol Clin (Engl Ed), 2021
Bustos-Merlo A, Rosales-Castillo A, Sotorrío Simo V.   +2 more
europepmc   +1 more source